Lipocine to host virtual r&d investor event to discuss lpcn 1154 (brlizio™) as a treatment for postpartum depression on july 9, 2025

Salt lake city , june 23, 2025 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it will host a virtual research and development (r&d) investor event on wednesday, july 9, 2025 at 11:00 am et featuring kristina m. deligiannidis, md (zucker hillside hospital, northwell health, new york), who will join company management to discuss the current treatment landscape and unmet needs in postpartum depression (ppd).
LPCN Ratings Summary
LPCN Quant Ranking